Dror Dicker

7 Keren Kayemet St, 49100
Petah Tiqwa, M, Israel

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 138 publications

Long-Term Health Care Utilization Costs of GLP-1RA Use vs Bariatric Metabolic Surgery.

Long-Term Health Care Utilization Costs of GLP-1RA Use vs Bariatric Metabolic Surgery.

Journal: JAMA network open

Published: July 01, 2026

Framework for the pharmacological treatment of obesity and its complications from the European Association for the Study of Obesity (EASO): 2026 update.

Framework for the pharmacological treatment of obesity and its complications from the European Association for the Study of Obesity (EASO): 2026 update.

Journal: Nature medicine

Published: May 12, 2026

Long-Term Weight Regain Outcome Post-Bariatric Surgery: Key Influencing Factors.

Long-Term Weight Regain Outcome Post-Bariatric Surgery: Key Influencing Factors.

Journal: Obesity surgery

Published: March 05, 2026

From risk factor to therapeutic target: obesity therapy and cardiovascular outcomes.

From risk factor to therapeutic target: obesity therapy and cardiovascular outcomes.

Journal: Heart (British Cardiac Society)

Published: February 23, 2026

Weight Loss as a Determinant of Histological Improvement in Metabolic Dysfunction-Associated Steatotic Liver Disease in People With Obesity. A Systematic Review and Network Meta-Analysis of Randomised Clinical Trials.

Weight Loss as a Determinant of Histological Improvement in Metabolic Dysfunction-Associated Steatotic Liver Disease in People With Obesity. A Systematic Review and Network Meta-Analysis of Randomised Clinical Trials.

Journal: Diabetes, obesity & metabolism

Published: January 05, 2026

Monlunabant in adults with obesity and metabolic syndrome: Open-label extension of a phase 2a trial.

Monlunabant in adults with obesity and metabolic syndrome: Open-label extension of a phase 2a trial.

Journal: Diabetes, obesity & metabolism

Published: December 12, 2025

CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1.

CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1.

Journal: Hypertension (Dallas, Tex. : 1979)

Published: December 02, 2025

Correction to: Epidemiology Landscape and Impact of Overweight and Obesity in Adults: Multi-country Results from the IMPACT-O Study.

Correction to: Epidemiology Landscape and Impact of Overweight and Obesity in Adults: Multi-country Results from the IMPACT-O Study.

Journal: Advances in therapy

Published: November 28, 2025

Initiation of GLP-1 Receptor Agonists Treatment after Bariatric Metabolic Surgery and Major Adverse Cardiac Events.

Initiation of GLP-1 Receptor Agonists Treatment after Bariatric Metabolic Surgery and Major Adverse Cardiac Events.

Journal: Obesity facts

Published: November 05, 2025

European Association for the Study of Obesity Position Statement on the Diagnosis and Management of Obesity in Older Adults.

European Association for the Study of Obesity Position Statement on the Diagnosis and Management of Obesity in Older Adults.

Journal: Obesity facts

Published: November 05, 2025

Comparative risks of dementia and Parkinson's disease with GLP-1 RAs versus other oral glucose-lowering medications in obese patients with type 2 diabetes: a large real-world cohort study.

Comparative risks of dementia and Parkinson's disease with GLP-1 RAs versus other oral glucose-lowering medications in obese patients with type 2 diabetes: a large real-world cohort study.

Journal: European journal of internal medicine

Published: November 04, 2025

Framework for the pharmacological treatment of obesity and its complications from the European Association for the Study of Obesity (EASO).

Framework for the pharmacological treatment of obesity and its complications from the European Association for the Study of Obesity (EASO).

Journal: Nature medicine

Published: October 02, 2025

Showing 1-12 of 138

Last Updated: 09/26/2026